🚀 VC round data is live in beta, check it out!
China Medical System Valuation Multiples
Discover revenue and EBITDA valuation multiples for China Medical System and similar public comparables like Corcept Therapeutics, LigaChem Biosciences, Humanwell Healthcare, Amicus Therapeutics and more.
China Medical System Overview
About China Medical System
China Medical System Holdings Ltd is active in the healthcare segment. It is one of the China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil, Salofalk, Combizym, and others.
Founded
2006
HQ
Employees
4.7K
Website
Sectors
Financials (LTM)
EV
$4B
China Medical System Financials
China Medical System reported last 12-month revenue of $1B and EBITDA of $308M.
In the same LTM period, China Medical System generated $910M in gross profit, $308M in EBITDA, and $238M in net income.
Revenue (LTM)
China Medical System P&L
In the most recent fiscal year, China Medical System reported revenue of $1B and EBITDA of $350M.
China Medical System expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $910M | XXX | $860M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $308M | XXX | $350M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $238M | XXX | $218M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
China Medical System Stock Performance
China Medical System has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
China Medical System's stock price is $1.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -2.0% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChina Medical System Valuation Multiples
China Medical System trades at 3.0x EV/Revenue multiple, and 12.1x EV/EBITDA.
EV / Revenue (LTM)
China Medical System Financial Valuation Multiples
As of April 11, 2026, China Medical System has market cap of $4B and EV of $4B.
Equity research analysts estimate China Medical System's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China Medical System has a P/E ratio of 18.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | 18.9x | XXX | 20.6x | XXX | XXX | XXX |
| EV/FCF | 24.2x | XXX | 27.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified China Medical System Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
China Medical System Margins & Growth Rates
China Medical System's revenue in the last 12 month grew by 22%.
China Medical System's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
China Medical System's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China Medical System's rule of X is 76% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
China Medical System Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
China Medical System Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Corcept Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| LigaChem Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Humanwell Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Amicus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Anthem Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China Medical System M&A Activity
China Medical System acquired XXX companies to date.
Last acquisition by China Medical System was on XXXXXXXX, XXXXX. China Medical System acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by China Medical System
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChina Medical System Investment Activity
China Medical System invested in XXX companies to date.
China Medical System made its latest investment on XXXXXXXX, XXXXX. China Medical System invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by China Medical System
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout China Medical System
| When was China Medical System founded? | China Medical System was founded in 2006. |
| Where is China Medical System headquartered? | China Medical System is headquartered in China. |
| How many employees does China Medical System have? | As of today, China Medical System has over 4K employees. |
| Is China Medical System publicly listed? | Yes, China Medical System is a public company listed on HKEX. |
| What is the stock symbol of China Medical System? | China Medical System trades under 00867 ticker. |
| When did China Medical System go public? | China Medical System went public in 2010. |
| Who are competitors of China Medical System? | China Medical System main competitors are Corcept Therapeutics, LigaChem Biosciences, Humanwell Healthcare, Amicus Therapeutics. |
| What is the current market cap of China Medical System? | China Medical System's current market cap is $4B. |
| What is the current revenue of China Medical System? | China Medical System's last 12 months revenue is $1B. |
| What is the current revenue growth of China Medical System? | China Medical System revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of China Medical System? | Current revenue multiple of China Medical System is 3.0x. |
| Is China Medical System profitable? | Yes, China Medical System is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of China Medical System? | China Medical System's last 12 months EBITDA is $308M. |
| What is China Medical System's EBITDA margin? | China Medical System's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of China Medical System? | Current EBITDA multiple of China Medical System is 12.1x. |
| What is the current FCF of China Medical System? | China Medical System's last 12 months FCF is $155M. |
| What is China Medical System's FCF margin? | China Medical System's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of China Medical System? | Current FCF multiple of China Medical System is 24.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.